Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Grant revenue $ 17,024
Operating expenses:    
Research and development 663,414 1,672,576
General and administrative 1,796,689 1,249,263
Total operating expenses 2,460,103 2,921,839
Loss from operations (2,460,103) (2,904,815)
Other income (expense):    
Interest income 19,235 62,201
Interest expense (7,085) (3,347)
Other income 1,124
Foreign currency exchange, net (2,880)
Total other income, net 9,270 59,978
Loss before income taxes (2,450,833) (2,844,837)
Income tax benefit
Net loss $ (2,450,833) $ (2,844,837)
Basic net loss per share $ (0.70) $ (1.41)
Diluted net loss per share $ (0.70) $ (1.41)
Shares used to compute basic net loss per share 3,496,078 2,204,766
Shares used to compute diluted net loss per share 3,496,078 2,204,766